Behavioral Study
Learn how FreeStyle Libre 3 System drives behavior change and diabetes self-management in adults with T2D on basal or non-insulin treatment4.
Achieve better clinical outcomes*1-3.
Explore the clinical evidence behind continuous glucose monitors (CGMs)—the FreeStyle Libre systems.
Clinical Analyses
Explore key medical advancements and related patient outcomes.
IMMEDIATE RCT
See how A1C was significantly reduced with FreeStyle Libre systems and DSME vs DSME alone in people with T2D*5.
GLP-1 Therapy
See how patients using a GLP-1 therapy experienced significant improvements in A1C after initiating FreeStyle Libre systems†6.
BGM = blood glucose monitoring; DSME = Diabetes Self-Management Education; T1D = Type 1 diabetes; T2D = Type 2 diabetes; RCT = randomized controlled trial
Case Studies
Discover how real patients benefit from using FreeStyle Libre systems and gain valuable, real-world insights.
Not actual image of user.
Debra, T2D patient:
See how the FreeStyle Libre 3 system helped Debra better understand her glucose levels, leading to improved medication adherence and TIR‡7.
Not actual image of user.
Joe, T2D patient:
Learn how the FreeStyle Libre 3 system helped Joe improve and maintain glycemic control even with GLP-1 interruption‡7.
Not actual image of user.
Female 65-70, T2D patient:
Discover how the FreeStyle Libre 2 system helped stabilize glucose and improve well-being in a patient struggling with glycemic variability and obesity‡7.
Not actual image of user.
Ben, T1D patient, newly diagnosed:
Explore how the FreeStyle Libre 2 system helped a patient averse to BGM increase medication adherence and glucose monitoring‡§7.
Not actual image of user.
Male T2D patient, chronic CV conditions:
See how the FreeStyle Libre 2 system helped increase scanning (vs with BGM), control, and awareness, leading to improved health and lifestyle choices‡7.
CV = cardiovascular; GLP-1 = glucagon-like peptide-1; QOL = quality of life; TIR = time in (target) range.
Learn about Joe's diabetes management journey
Hear Dr. Paul share the journey of her patient, Joe, a T2D patient that used the FreeStyle 3 Libre system to improve and maintain glycemic control‡7.
American Diabetes Association (ADA) Guidelines
Join us at an upcoming event!
Mark your calendar to meet industry experts, connect with peers, and learn more about our latest innovations.
* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
† Real-world study that utilized a linked electronic health records (EHR)-claims database and included adults with T2D and HbA1c ≥8% who acquired their first GLP-1 2018-2022.
‡ Based on assessment and input from patient’s healthcare provider.
§ Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
References: 1. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 388, no. 10057 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 2. Evans, Mark, et al. "Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies." Diabetes Therapy (April 2022). https://doi.org/10.1007/s13300-022-01253-9. 3. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 4. Polonsky, W. H. How CGM Use Affects Diabetes-Related Attitudes and Behaviors in People with T2D: A Qualitative Investigation.” Poster presentation at ADA 2025: 85th Scientific Sessions, 20-23 June 2025, Chicago, United States. Diabetes (2025): https://doi.org/10.2337/db25-2036-LB. 5. Aronson, Ronnie, et al. “IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes Obesity and Metabolism 25, no. 4 (2023): 1024–1031. https://doi.org/10.1111/dom.14949. 6. Miller, Eden, et al. “Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.” Diabetes Therapy 15, no. 9 (September 2024): 2027–2038. https://doi.org/10.1007/s13300-024-01619-1. 7. Data on file. Abbott Diabetes Care, Inc.
ADC-95730 v3.0
Important Safety Information
Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Get medical attention when appropriate. Abbott Customer Service at 855-632-8658 or visit FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-45115 v23.0
